Loading stock data…
Amarin Corporation plc (AMRN)
$16.21+0.30 (+1.89%)
Market OpenUpdated 2:03 PM EDT
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amarin Corporation plc in the Healthcare sector is trading at $16.21 with a market capitalization of $323M. Wall Street consensus targets $12.50 (2 analysts), implying a -22.9% move over the next 12 months. The stock is currently 22% below its 52-week high of $20.90, remaining 5.1% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -22.9% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $45.13M↓ | $49.22M↓ | $49.67M↓ | $72.74M↑ | $42.02M |
| Gross Profit | $17.77M↓ | $23.17M↑ | $22.21M↓ | $50.36M↑ | $25.13M |
| Operating Income | -$8.01M↓ | -$2.26M↓ | -$1.70M↓ | $6.77M↑ | -$16.75M |
| Net Income | -$10.51M↓ | -$1.22M↑ | -$7.74M↑ | -$14.14M↑ | -$15.70M |
Peer Comparison
JNJUNHPFE
Fundamentals
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$322.51M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-7.48%
Volume
Today's trading volume
46,768
Recent News
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading
European equities traded in the US as American depositary receipts were trending higher late Monday
Here's Why You Should Add ANIX Stock to Your Portfolio Now
Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phase II study and expanding intellectual property protection.
Reasons Why Investors Should Consider Betting on Indivior Stock
INDV's Sublocade reaches 500,000+ U.S. patients. Management expects faster 2026 growth through cost optimization and strong execution.
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
European equities traded in the US as American depositary receipts started the week higher late Mond
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
Here is how Amarin (AMRN) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.